This study was a prospective, randomized design to compare oxygenation and pulmonary hemodynamics between inhaled nitric oxide (NO) and inhaled prostacylcin (PGI,), and between inhaled and i.v. PGI, in acute respiratory failure with pulmonary hypertension. Acute respiratory failure with pulmonary hypertension was induced in 12 piglets weighing 9-12 kg by repeated lung lavages and a continuous infusion of the stable endoperoxane analogue of thromboxane. Thereafter the animals were randomly assigned either for NO or PGI, application. All animals were treated with different concentrations of NO or different doses of PGI, applied i.v. and inhaled in random order. Continuous monitoring included ECG, central venous pressure (CVP), mean pulmonary artery pressure (MPAP), mean arterial pressure (MAP), artertial oxygen saturation (SaO,), and mixed venous oxygen saturation (SvO,) measurements. NO inhalation of 10 ppm resulted in a significant increase in Pao,/fraction of inspired oxygen (FiO,) from 7.5 2 1.34 kPa to 46.1 2 9.7 kPa. MPAP decreased significantly from 5.1 -t 0.26 kPa to 3.7 i 0.26 kPa during inhaled NO of 40 ppm; i.v. infusion of PGI, slightly increased oxygenation parameters. A significant increase in Pao,/ FiO, up to 32.4 2 3.lkPa was observed during PGI, aerosol delivery (11 < 0.01); i.v. PGI, decreased MAP from 11.5 -+ 0.39 kPa to 9.8 2 0.66 kPa ( p < 0.05) and MPAP from 5.8 -+ 0.53 kPa to 4.5 2 0.66 kPa, respectively ( p < 0.05). PGI, aerosol delivery significantly decreased the MPAP to 3.7 2 0.53 kPa ( p < 0.05) without influencing the MAP. It was concluded that inhaled NO and inhaled PGI, act as selective pulmonary vasodilators in acute respiratory Cdilure with pulmonary hypertension In 1987 N O was reported to be an important endotheliumderived relaxing factor (1, 2). NO is synthesized in the vascular endothelial cell from L-arginine by NO synthase. It rapidly diffuses into the vascular smooth muscle cell and acts by stimulation of guanylate cyclase producing cGMP which me-
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nates, infants, and adults with pulmonary hypertension or acute respiratory failure combined with pulmonary hypertension (12) (13) (14) (15) (16) (17) (18) (19) . Inhaled NO improves ventilationlperfusion mismatch by selectively vasodilating pulmonary vessels of ventilated areas.
PGI,, an arachidonic acid metabolite, is a potent dilator of the arterial and venous vessels by increasing the concentration of CAMP in vascular smooth muscle cells (20) . PGI, has been applied in a variety of clinical and experimental conditions with pulmonary hypertension (21) (22) (23) (24) (25) . However, vasodilation occurs in both the pulmonary and systemic vessels which might result in systemic hypotension. In addition, as PGI, vasodilates pulmonary vessels in ventilated and nonventilated areas of the lung, increased intrapulmonary shunt with increased venous admixture might occur. Recently, aerosolized PGI, has been reported both in clinical and experimental settings to be a selective pulmonary vasodilator without side effects on the systemic vasculature (26, 27) .
The aim of this study is to compare the pulmonary and hemodynamic effects of inhaled NO and inhaled PGI, in an animal model of acute respiratory failure with pulmonary hypertension. In addition, we evaluated the differences between inhaled and i.v. PGI, on the pulmonary and hemodynamic effects.
METHODS
The protocol was approved by the Institutional Animal Research Committee and the care of the animals was in accordance with guidelines for ethical animal research.
In 1 2 piglets of either sex, weighing 10 ? 0.6 kg, premedicated with azaperone (8 mgikg) and atropine (0.02 mglkg), anesthesia was induced with ketamine (10 mglkg) and thereafter maintained by a continuous infusion of fentanyl (0.15 ~g/kg/min), pentobarbital sodium (4 mg/kg/h), and pancuronium (0.3 mgikglh). After placing a 5.5-mm inside diameter Hi-Lo cuffed tube (Hi-Lo jet tube, National Catheter Corp., Malinckrodt, Glen Falls, NY) via tracheostomy, controlled mechanical ventilation was established using a volume controlled, time cycled ventilator (Veolar, Hamilton Comp., Rhaziins, Switzerland). Tidal volume was set at 10-12 mLlkg, respiratory rate at 2O/min, inspiratory/expiratory ratio at 1:2, PEEP at 4 cmH,O, and FiO, at 0.21. Initially a 4 Fr doublelumen catheter (Duocath, Peter von Berg Medizintechnik, Kirchseeon, FRG) was inserted into the right subclavian vein for nutrition and anesthesia. After induction of anesthesia, a Ringer solution was infused, initially, at a rate of 10 mLlkg in 30 min followed by a continuous infusion of 5 mL/kg/h. A 5.5 Fr thermodilution 0, saturation fiber-optic pulmonary artery catheter (Edwards Swan-Ganz Oximetry TD catheter, Edwards Critical Care Division, Irvine, CA) was placed into the pulmonary artery by peripheral cutdown of the external jugular vein. A 4 Fr 0, saturation catheter (Edslab double lumen 0, Sat I1 catheter, Edwards Critical Care Division) was inserted via the right common carotid artery and placed into the thoracic aorta for continuous arterial oximetry measurement. A short 16-gauge catheter (Abbocath, Abbott Ireland LTD, Sligo, Republic of Ireland) was placed into the femoral artery for continuous pressure recording. A second 4 Fr double-lumen catheter (Duocath, Peter von Berg Medizintechnik) was placed via the left external jugular vein.
Hemodynamic monitoring. Heart rate and rhythm, right atrial, pulmonary artery, and peripheral artery pressures were recorded continuously on a multichannel recorder (SMU 612 monitor, PPG Hellige Corp., Freiburg, IFRG) using 0.9% saline filled transducers (Monitoring Kit NM-081-D, Peter von Berg Medizintechnik). All pressures were referenced to the midthorax. Cardiac output was measured at end-expiration by the thermodilution technique as the mean of three determinations after injection of 5 mL 0°C 0.9% saline. SVR was calculated as MAP divided by cardiac output. PVR was calculated as MPAP divided by cardiac output. Two oxygen saturation monitors (Baxter Sat2 Oximeter; Baxter Healtl~care Corporation, Edwards Critical Care Division, Irvine, CA) were used for continuous arterial and mixed venous oximetry measurements.
Respiratory monitoring. Arterial and mixed venous blood samples were taken for measurements of Hb, oxygen saturation, Po,, Pco,, and pH using an automatic blood gas system (AVL 995, AVL Corp., Graz, Austria). In addition the SaO, and SvO, oxygen saturations and arterial methemoglobin fraction (CO-Oxylite AVL 912, AVL Corp.) were analyzed. Endtidal CO, concentrations and the fraction of inspired and expired oxygen were measured with a multigas analyzer (PPG Hellige Corp., Freiburg, FRG). Airway pressures, tidal volume, Cst, and Raw were measured with a Bicore CP-100 monitor (Bicore Monitoring Systems, Irvine, CA).
Administration of PGZ2 PGI, was supplied as the sodium salt of epoprostenol (Flolan, Wellcome, London, UK) dissolved in glycine buffer and diluted with 0.9% saline at a concentration of 10 pglml. It was applied as an aerosol or as continuous infusion at the same concentration. For inhalation of PGI, as aerosol a nebulizer chamber (Intersurgical Ltd., Twickenham, UK) and an oxygen flowmeter (Drager Austria GesmbH., Vienna, Austria) with flow rates of 3-6 Llmin was used. The aerosol was delivered at the connection of the ventilatory circuit with the flow sensor of the ventilatory circuit (MR 390 15 mm tubings, Fisher & E'aykel Healthcare, Panmure, Auckland, NZ) near the endotracheal tube. Primarily, the nebulizer chamber was filled with 1 ml, of the above described PGI, solution followed by a continuous infusion of 30-60 nglkglmin into the nebulizer chamber via a 20-gauge catheter (Venflon, Viggo-Spectramed, Helsinborg, Sweden) inserted into a small bored side hole of the nebulizer chamber. During aerosol delivery of PGI, the tidal volume of the ventilator was reduced to obtain comparable mean airway pressures. Intravenous infusion of PGI, was started at 5 nglkglmin and was subsequently increased up to 40 ng/k,gJmin.
Administration of NO. NO was obtained as 900 ppm in nitrogen (Pulmomix forte, Messer-Criesheim, Austria) and applied using the Pulmonox system. The Pulmonox is a microprocessor controlled system which allows NO delivery at concentrations from 1 to 40 ppm and continuous inspiratory measurement of NO/NO, using the chemiluminescence method. A flow-box incorporated into the inspiratory limb of the ventilatory circuit transfers the inspiratory flow rate of the ventilator to the Pulmonox system which adapts the NO dosage on a continuous basis. NO was administered into the inspiratory limb of the ventilatory circuit close to the endotracheal tube using an airway sampling adapter (Engstrom Sampling adapter, Gambro Engstrom, Bromma, Sweden). The system was calibrated before each treatmentlmeasurement with special calibration gases.
Protocol. After this instrumentation the animals were allowed to rest for 30 min before control measurements were performed. Before starting the lung lavage procedure the FiO, of the ventilator was increased to 1.0 and the PEEP levels to 1 kPa. In addition, a Tris infusion was started to obtain a stable pH throughout the study period. Acute respiratory failure (SaO, < 85%) was induced by repeated lung lavages using 0.9% saline (20-30 mL/kg/lavage). After the last lung lavage the stable endoperoxide analog of thromboxane (U46619, Cascade Biochem Ltd., Bershire, UK) was infused at a rate of 0.4-0.8 pg/kg/min to increase the mean PAP above 4.6 kPa. Thereafter the animals were randomly assigned either for NO or PGI, application. To obtain a pulmonary vasodilator doseresponse curve during U46619 infusion all animals were treated with different concentrations of NO (1, 2, 5, 10, 20, and 40 ppm) or different doses of PGI, (5, 10, 20 , and 40 ng/kg/min as continuous i.v. infusion and 30 and 60 nglkgtmin as an aerosol). Intravenous and inhaled PGI, were applied in random order. Measurements were taken after 10-15 min of each NO concentration or PGI, dosis or after a stable period of 5 min. Five minutes after termination of NO or PGI, application a last measurement was taken under hypoxic conditions.
All animals tolerated the experimental protocol. After the end of the trial the animals were killed with an overdose of potassium chloride.
Data analysis.
Values are given as mean + SEM. Initially a multifactorial analysis of variance for repeated measures was applied using the Statview 4.0 software for Macintosh. If a significant difference was determined, the intragroup differences were determined using the paired t test and the intergroup differences by unpaired t test with a p value of <0.05 being considered significant.
RESULTS
Three to six lung lavages significantly decreased Cst from 1.7 t 0.04 to 0.84 + 0.02 mL/kPa/kg ( p < 0.01) and Pao2/ FiO, from 65.2 + 1.5 to 8.2 2 0.5 kPa ( p < 0.01). Simultaneously Raw increased from 4.6 -C 0.13 to 7.4 + 0.3 kPa/L/s ( p < 0.01). The infusion of U46619 significantly increased MPAP and PVR by 141 and 321%, respectively ( p < 0.01).
NO. Blood gas parameters, arterial and mixed venous oxygen saturations, mean airway pressure, and intrapulmonary shunt fraction are summarized in Table 1 . NO inhalation resulted in a significant increase in oxygenation parameters. The highest Pao,/FiO, values of 46.1 t 9.7 kPa were observed during inhalation of 10 ppm NO. A further increase in the NO concentration resulted in a slight decrease in Pao,/FiO, values. When NO concentration was stepwise increased from 1 to 40 ppm, FiO, decreased from 1.0 to 0.9 +-0.05 ( p < 0.01). Qs/Qt improved significantly during NO inhalation of 10-40 ppm. No significant differences were observed in pulmonary mechanics during NO inhalation.
The hemodynamic parameters during NO inhalation are summarized in Table 2 . There was no change in heart rate, CVP, MAP, and PVR during inhaling different doses of NO.
MPAP decreased significantly from 5.1 + 0.02 kPa to 3. PGZ,. Blood gas parameters, arterial and mixed venous oxygen saturations, mean airway pressure, and intrapulmonary shunt fraction are given in Table 3 . Intravenous infusion of PGI, slightly increased oxygenation parameters. The highest Pao,/FiO, values of 14.1 2 4.1 kPa were observed during infusion of 40 nglkglmin of PGI,. A significant increase in Pao,/FiO, up to 32.4 t 3.1 kPa was observed during PGI, inhalation ( p < 0.01). During inhaled PGI, the Qs/Qt values were significantly lower than during i.v. PGI, application ( p < 0.05). Pulmonary mechanics (Cst, Raw) did not change significantly during inhaled and i.v. PGI, application. During i.v. PGI, application, MAP and MPAP decreased by 15 and 23%, respectively ( p < 0.05), and heart rate increased by 18% ( p < 0.05). There was no change in PVR and SVR. PGI, aerosol application did not change heart rate, MAP, and CVP. However, a significant decrease in MPAP and PVR by 22 and 36%, respectively (p < 0.05) was observed. ..
PGI, aerosol application. However, there was a significant difference in these parameters between NO inhalation and i.v. PGI, application. After termination of both treatments, oxygenation and hernodynamic deteriorated within 2-5 min in all animals.
DISCUSSION
Acute respiratory failure in neonates, infants, and adults is often associated with pulmonary hypertension. In an early stage of acute lung injury, pulmonary hypertension is mediated u 4661 9 ~nfusion by vasoactive substances (28) , whereas in the late phase strut- animal model severe acute respiratory failure with pulmonary hypertension was simulated by repeated lung lavages and continuous infusion of U46619.
The main finding of our study was that both inhaled PGI, and inhaled NO act as selective pulmonary vasodilators with improvement in oxygenation and pulmonary hemodynamics without causing systemic vasodilation.
PGI, is the main metabolite of arachidonic acid produced in endothelial cells with potent vasodilating properties of both the arterial and venous vasculature. It has been successfully used in a variety of experimental conditions and patients with pulmonary hypertension (21) (22) (23) (24) (25) . The dosis of i.v. PGI, application ranges from 5-35 nglkgimin. The limitations of i.v. applied PGI, as a nonselective vasodilator are its risk to systemic hypotension and its possible risk to increased intrapulmonary shunting by vasodilating pulmonary vessels of ventilated and nonventilated areas. Recently, PGI, was applied 0 : observed a decrease of PVR by 30% and a significant increase of Pao,/FiO, from 15.9 i-2.4 kPa to 22.8 i . 1.6 kPa. The authors concluded that redistribution of blood flow from nonventilated to aerosol-accessible areas resulted in improved matching of ventilation and perfusion and improved oxygenation. In addition, they speculated that an increase in the dose of aerosolized PGI, might cause "spillover" of the prostanoid into the systemic circulation. In 1993 Welte et al. (27) reported their investigation on the effects of PGI, aerosol on pulmonary and systemic circulation compared with NO inhalation in 6 dogs with hypoxic pulmo- 
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increased levels of prostanoids in bronchoalveolar lavage of patients with ARDS (30) . In addition, increased levels of circulatory thromboxane A,, a potent vasoconstrictor, may be responsible for pulmonary hypertension in ARDS (31). In our vasodilation. NO inhalation of 50 ppm decreased PAP and PVR by 76% and 73%, respectively. The authors concluded that aerosolized PGI, is a selective pulmonary vasodilator, but less potent than inhaled NO, in hypoxia induced pulmonary hypertension. In our study inhaled PGI, significantly improved oxygenation, reduced QsIQt, PAP, and PVR with no influence on the systemic vasculature. Intravenous PGI, slowly improved oxygenation. In contrast to other findings doses up to 40 ng/kg/min did not increase Qs/Qt. Whereas PAP decreased significantly during i.v. PGI, infusion MAP remained stable up to a PGI, infusion rate of 10 ngtkglmin. However, a significant decrease in MAP was noticed during infusion of 40 nglkgimin of PGI,. The PVRISVR ratio was significantly lower during inhaled PGI, than during i.v. PGI, indicating the local vasodilating effect of inhaled PGI,. In our study the inhaled PGI, dose of 30-60 nglkglmin was significantly higher than the dose applied by Welte et al. (27) in dogs and slightly higher than the dose applied to humans with ARDS (26) . The real aerosol deposit in the lungs is rather small (<5%) (31, 32) and cannot be easily determined. In our animal trial we did not measure PGI, aerosol particles in the airways and did not measure PGI, metabolites in the circulation. However, from the clinical point of view the inhaled PGI, aerosol was effective in terms of improved oxygenation and pulmonary circulation without negative systemic vascular effects. However, the exact dose and the optimal form of PGI, aerosol delivery has to be shown in further studies. Inhaled PGI, was reported to have bronchodilatory effects in asthma (33) . However, our results did not show any effect on Raw either during PGI, infusion or aerosol therapy. Inhaled NO has been demonstrated to be beneficial in adults with pulmonary hypertension (19) and ARDS (18) , infants and children with ARDS (17) and pulmonary hypertension associated with congenital heart disease (33), and neonates with pulmonary hypertension (13). Inhaled NO has been shown to reverse acute pulmonary vasoconstriction induced by hypoxia, by a thromboxane analog, or by the heparin-protamin reaction (7, 8) . The vasodilator effect of inhaled NO occurred selectively in the pulmonary vessels without causing systemic vasodilation. Recently, Etches et al. (12) reported that NO reverses acute hypoxic pulmonary hypertension in the newborn piglet. The animals were given varying concentrations of inhaled NO between 5 and 80 ppm. All doses of NO significantly reduced PAP and PVR with no significant differences between the various doses of NO (12) . In our present study a significant increase in oxygenation and a significant decrease in PAP occurred at an inhaled NO concentration of 1 ppm. Furthermore, oxygenation improved constantly with increasing NO concentrations up to 10 ppm. However, further increases in inhaled NO concentration resulted in a slight decrease in oxygenation. This might be due to a lower FiO, (FiO, 0.9 at 40 pprn NO versus 1.0-0.98 at 1-10 pprn NO). The lowest PAP levels were seen during 40 pprn of NO. Although PAP decreased significantly in our study, there was no change in PVR. The continuous infusion of U46619 constantly increased systemic vasoconstriction resulting in a gradual decline in cardiac output. The PVRJSVR ratio decreased significantly during NO inhalation, indicating the local vasorelaxing effect of inhaled NO. Recently, Gerlach et al. (35) observed improved oxygenation in adults with ARDS with unchanged PAP at very low concentrations of inhaled NO (<1 pprn). They concluded that improved oxygenation results from redistribution of blood flow from nonventilated to ventilated areas of the lungs and not from enhanced pulmonary perfusion.
In our study the Pao,/FiO, ratio was higher and QsJQt was lower during inhaled NO of 10 pprn than during inhaled PGI,. Both inhalational therapies decreased significantly the PAP without any influence on MAP. These findings indicate that both inhaled substances decrease PAP sufficiently and that inhaled NO better improves ventilation-perfusion imbalance than inhaled PGI,. Dupuy et al. (36) demonstrated in guinea pigs that inhaled NO reduced the increased pulmonary resistance induced by an i.v. methacholine infusion by 50%. In contrast Zayek et al. (11) could not find any effect of inhaled NO on Raw and tidal volume in newborn lambs with pulmonary hypertension. Our results confirm this finding.
NO is rapidly converted to NO, and other toxic oxides of nitrogen by oxidation that can be toxic to the lungs. Greenbaum et al. (6) published that inhalation of 2% NO or NO, resulted in death due to methemoglobinemia, hypoxemia, and pulmonary edema. The conversion of NO to NO, depends on the NO concentration, the FiO,, and the contact time of both inspired concentrations of NO, were measured to be less than 0.5 pprn even at NO concentrations of 40 ppm. NO is rapidly bound to Hb in the vascular system producing methemoglobin. NO concentrations up to 80 ppm did not increase methemoglobin concentrations in animal trials ('7). We measured methemoglobin concentrations up to 2% during NO inhalation of 40 ppm. However, critical levels of methemoglobinemia with reduced oxygen transport might follow prolonged inhalation of high doses of NO. Because of the possible toxicities, as methemoglobinemia due to NO and direct pulmonary injury due to NO,, NO should be applied caut!iously with continuous monitoring of inspiratory NO and NO, concentrations.
In conclusion, both inhaled NO and IPGI, act as a selective pulmonary vasodilators in acute respiratory failure with pulmonary hypertension resulting in irnproved oxygenation mainly due to improved mismatch of pulmonary perfusion and ventilation. Both inhaled substances have no effects on Raw and Cst. The application of inhaled NO is rather simple. Because of its possible toxicity, inhaled NO requires measurement of NO and NO, on a continuous basis. As aerosolized PGI, has no known toxic side effects, measurement of the inspired concentration is not necessary. However, the exact dose and aerosol application form has to be investigated in further studies. Intravenous PGI, improves oxygenation and pulmonary hemodynamics to a less extent than aerosolized PGI, and has the risk of systemic hypotension at a higher dose.
